Cytokinetics’ Myqorzo Succeeds Where Camzyos Failed: Positive Phase 3 Results in Non-Obstructive HCM

Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.